MedTrace Logo

Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients

NCT03385538 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2017-12-28

No results posted yet for this study

Summary

Personalized therapy as prophylaxis in ischemic stroke patients is not yet an option. From patients with ischemic heart disease, we know that patients with in vitro high on treatment platelet reactivity (HTPR) have an increased risk of stent thrombosis following per-cutaneous coronary intervention. Other studies have shown association of CYP2C19 genotypes with different responses to the anti platelet drug Clopidogrel. We measure HTPR in ischemic stroke patients on increasing doses of clopidogrel and investigate the CYP2C19 genotype for each patient.

Conditions

Interventions

DRUG

Clopidogrel

increasing doses of clopidogrel depending on PRU values (75-300 mg)

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Charlotte Rath, MD · Zealand University Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2017-07-30
Completion
2017-07-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03385538 on ClinicalTrials.gov